AustralieFrV1, PascalFrancis, Corpus, bibRecord, 002A17

Management of behavioral problems in Alzheimer's disease

Identifieur interne : 002A17 ( PascalFrancis/Corpus ); précédent : 002A16; suivant : 002A18

Management of behavioral problems in Alzheimer's disease

Auteurs : Serge Gauthier ; Jeffrey Cummings ; Clive Ballard ; Henry Brodaty ; George Grossberg ; Philippe Robert ; Constantine Lyketsos

Source :

International psychogeriatrics [ 1041-6102 ] ; 2010.

RBID : Francis:10-0266370

Descripteurs français

Pascal (Inist)
- Gestion, Trouble du comportement, Démence d'Alzheimer, Comportement, Traitement, Personne âgée.

English descriptors

KwdEn :
- Alzheimer disease, Behavior, Behavioral disorder, Elderly, Management, Treatment.

Abstract

Alzheimer's disease (AD) is a complex progressive brain degenerative disorder that has effects on multiple cerebral systems. In addition to cognitive and functional decline, diverse behavioral changes manifest with increasing severity over time, presenting significant management challenges for caregivers and health care professionals. Almost all patients with AD are affected by neuropsychiatric symptoms at some point during their illness; in some cases, symptoms occur prior to diagnosis of the dementia syndrome. Further, behavioral factors have been identified, which may have their origins in particular neurobiological processes, and respond to particular management strategies. Improved clarification of causes, triggers, and presentation of neuropsychiatric symptoms will guide both research and clinical decision-making. Measurement of neuropsychiatric symptoms in AD is most commonly by means of the Neuropsychiatric Inventory; its utility and future development are discussed, as are the limitations and difficulties encountered when quantifying behavioral responses in clinical trials. Evidence from clinical trials of both non-pharmacological and pharmacological treatments, and from neurobiological studies, provides a range of management options that can be tailored to individual needs. We suggest that non-pharmacological interventions (including psychosocial/psychological counseling, interpersonal management and environmental management) should be attempted first, followed by the least harmful medication for the shortest time possible. Pharmacological treatment options, such as antipsychotics, antidepressants, anticonvulsants, cholinesterase inhibitors and memantine, need careful consideration of the benefits and limitations of each drug class.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 1041-6102`
A03		`1`		`@0 Int. psychogeriatr.`
A05				`@2 22`
A06				`@2 3`
A08	`01`	`1`	`ENG`	`@1 Management of behavioral problems in Alzheimer's disease`
A11	`01`	`1`		`@1 GAUTHIER (Serge)`
A11	`02`	`1`		`@1 CUMMINGS (Jeffrey)`
A11	`03`	`1`		`@1 BALLARD (Clive)`
A11	`04`	`1`		`@1 BRODATY (Henry)`
A11	`05`	`1`		`@1 GROSSBERG (George)`
A11	`06`	`1`		`@1 ROBERT (Philippe)`
A11	`07`	`1`		`@1 LYKETSOS (Constantine)`
A14	`01`			`@1 Alzheimer's Disease and Related Disorders Unit at the McGill Centerfor Studies in Aging Douglas Mental Health University Institute @2 Montreal @3 CAN @Z 1 aut.`
A14	`02`			`@1 Mary S. Easton Center for Alzheimer's Disease Research at UCLA @2 Los Angeles, California @3 USA @Z 2 aut.`
A14	`03`			`@1 Age Related Diseases, King's College London @2 London @3 GBR @Z 3 aut.`
A14	`04`			`@1 Primary Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales @2 Sydney @3 AUS @Z 4 aut.`
A14	`05`			`@1 Department of Neurology and Psychiatry, St Louis University School of Medicine @2 St Louis, Missouri @3 USA @Z 5 aut.`
A14	`06`			`@1 Centre Mémoire de Ressources et de Recherche (Memory Centre for Care and Research), CHU de Nice, Hôpital Pasteur @2 Nice @3 FRA @Z 6 aut.`
A14	`07`			`@1 Department of Psychiatry, The Johns Hopkins Bayview Medical Center @2 Baltimore, Maryland @3 USA @Z 7 aut.`
A20				`@1 346-372`
A21				`@1 2010`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 26959 @5 354000181144060020`
A44				`@0 0000 @1 © 2010 INIST-CNRS. All rights reserved.`
A45				`@0 7 p.`
A47	`01`	`1`		`@0 10-0266370`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 International psychogeriatrics`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Alzheimer's disease (AD) is a complex progressive brain degenerative disorder that has effects on multiple cerebral systems. In addition to cognitive and functional decline, diverse behavioral changes manifest with increasing severity over time, presenting significant management challenges for caregivers and health care professionals. Almost all patients with AD are affected by neuropsychiatric symptoms at some point during their illness; in some cases, symptoms occur prior to diagnosis of the dementia syndrome. Further, behavioral factors have been identified, which may have their origins in particular neurobiological processes, and respond to particular management strategies. Improved clarification of causes, triggers, and presentation of neuropsychiatric symptoms will guide both research and clinical decision-making. Measurement of neuropsychiatric symptoms in AD is most commonly by means of the Neuropsychiatric Inventory; its utility and future development are discussed, as are the limitations and difficulties encountered when quantifying behavioral responses in clinical trials. Evidence from clinical trials of both non-pharmacological and pharmacological treatments, and from neurobiological studies, provides a range of management options that can be tailored to individual needs. We suggest that non-pharmacological interventions (including psychosocial/psychological counseling, interpersonal management and environmental management) should be attempted first, followed by the least harmful medication for the shortest time possible. Pharmacological treatment options, such as antipsychotics, antidepressants, anticonvulsants, cholinesterase inhibitors and memantine, need careful consideration of the benefits and limitations of each drug class.
C02	`01`	`X`		`@0 770D05 @1 IV`
C02	`02`	`X`		`@0 770D03M @1 IV`
C03	`01`	`X`	`FRE`	`@0 Gestion @5 01`
C03	`01`	`X`	`ENG`	`@0 Management @5 01`
C03	`01`	`X`	`SPA`	`@0 Gestión @5 01`
C03	`02`	`X`	`FRE`	`@0 Trouble du comportement @5 02`
C03	`02`	`X`	`ENG`	`@0 Behavioral disorder @5 02`
C03	`02`	`X`	`SPA`	`@0 Trastorno conducta @5 02`
C03	`03`	`X`	`FRE`	`@0 Démence d'Alzheimer @5 03`
C03	`03`	`X`	`ENG`	`@0 Alzheimer disease @5 03`
C03	`03`	`X`	`SPA`	`@0 Demencia Alzheimer @5 03`
C03	`04`	`X`	`FRE`	`@0 Comportement @5 04`
C03	`04`	`X`	`ENG`	`@0 Behavior @5 04`
C03	`04`	`X`	`SPA`	`@0 Conducta @5 04`
C03	`05`	`X`	`FRE`	`@0 Traitement @5 05`
C03	`05`	`X`	`ENG`	`@0 Treatment @5 05`
C03	`05`	`X`	`SPA`	`@0 Tratamiento @5 05`
C03	`06`	`X`	`FRE`	`@0 Personne âgée @5 18`
C03	`06`	`X`	`ENG`	`@0 Elderly @5 18`
C03	`06`	`X`	`SPA`	`@0 Anciano @5 18`
C07	`01`	`X`	`FRE`	`@0 Homme`
C07	`01`	`X`	`ENG`	`@0 Human`
C07	`01`	`X`	`SPA`	`@0 Hombre`
C07	`02`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 37`
C07	`02`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`02`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 38`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 38`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 38`
C07	`04`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 39`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 39`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 39`
C07	`05`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 40`
C07	`05`	`X`	`ENG`	`@0 Nervous system diseases @5 40`
C07	`05`	`X`	`SPA`	`@0 Sistema nervioso patología @5 40`
N21				`@1 172`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	FRANCIS 10-0266370 INIST
ET :	Management of behavioral problems in Alzheimer's disease
AU :	GAUTHIER (Serge); CUMMINGS (Jeffrey); BALLARD (Clive); BRODATY (Henry); GROSSBERG (George); ROBERT (Philippe); LYKETSOS (Constantine)
AF :	Alzheimer's Disease and Related Disorders Unit at the McGill Centerfor Studies in Aging Douglas Mental Health University Institute/Montreal/Canada (1 aut.); Mary S. Easton Center for Alzheimer's Disease Research at UCLA/Los Angeles, California/Etats-Unis (2 aut.); Age Related Diseases, King's College London/London/Royaume-Uni (3 aut.); Primary Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales/Sydney/Australie (4 aut.); Department of Neurology and Psychiatry, St Louis University School of Medicine/St Louis, Missouri/Etats-Unis (5 aut.); Centre Mémoire de Ressources et de Recherche (Memory Centre for Care and Research), CHU de Nice, Hôpital Pasteur/Nice/France (6 aut.); Department of Psychiatry, The Johns Hopkins Bayview Medical Center/Baltimore, Maryland/Etats-Unis (7 aut.)
DT :	Publication en série; Niveau analytique
SO :	International psychogeriatrics; ISSN 1041-6102; Etats-Unis; Da. 2010; Vol. 22; No. 3; Pp. 346-372; Bibl. 7 p.
LA :	Anglais
EA :	Alzheimer's disease (AD) is a complex progressive brain degenerative disorder that has effects on multiple cerebral systems. In addition to cognitive and functional decline, diverse behavioral changes manifest with increasing severity over time, presenting significant management challenges for caregivers and health care professionals. Almost all patients with AD are affected by neuropsychiatric symptoms at some point during their illness; in some cases, symptoms occur prior to diagnosis of the dementia syndrome. Further, behavioral factors have been identified, which may have their origins in particular neurobiological processes, and respond to particular management strategies. Improved clarification of causes, triggers, and presentation of neuropsychiatric symptoms will guide both research and clinical decision-making. Measurement of neuropsychiatric symptoms in AD is most commonly by means of the Neuropsychiatric Inventory; its utility and future development are discussed, as are the limitations and difficulties encountered when quantifying behavioral responses in clinical trials. Evidence from clinical trials of both non-pharmacological and pharmacological treatments, and from neurobiological studies, provides a range of management options that can be tailored to individual needs. We suggest that non-pharmacological interventions (including psychosocial/psychological counseling, interpersonal management and environmental management) should be attempted first, followed by the least harmful medication for the shortest time possible. Pharmacological treatment options, such as antipsychotics, antidepressants, anticonvulsants, cholinesterase inhibitors and memantine, need careful consideration of the benefits and limitations of each drug class.
CC :	770D05; 770D03M
FD :	Gestion; Trouble du comportement; Démence d'Alzheimer; Comportement; Traitement; Personne âgée
FG :	Homme; Pathologie de l'encéphale; Maladie dégénérative; Pathologie du système nerveux central; Pathologie du système nerveux
ED :	Management; Behavioral disorder; Alzheimer disease; Behavior; Treatment; Elderly
EG :	Human; Cerebral disorder; Degenerative disease; Central nervous system disease; Nervous system diseases
SD :	Gestión; Trastorno conducta; Demencia Alzheimer; Conducta; Tratamiento; Anciano
LO :	INIST-26959.354000181144060020
ID :	10-0266370

Links to Exploration step

Francis:10-0266370

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Management of behavioral problems in Alzheimer's disease</title>
<author><name sortKey="Gauthier, Serge" sort="Gauthier, Serge" uniqKey="Gauthier S" first="Serge" last="Gauthier">Serge Gauthier</name>
<affiliation><inist:fA14 i1="01"><s1>Alzheimer's Disease and Related Disorders Unit at the McGill Centerfor Studies in Aging Douglas Mental Health University Institute</s1>
<s2>Montreal</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Cummings, Jeffrey" sort="Cummings, Jeffrey" uniqKey="Cummings J" first="Jeffrey" last="Cummings">Jeffrey Cummings</name>
<affiliation><inist:fA14 i1="02"><s1>Mary S. Easton Center for Alzheimer's Disease Research at UCLA</s1>
<s2>Los Angeles, California</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ballard, Clive" sort="Ballard, Clive" uniqKey="Ballard C" first="Clive" last="Ballard">Clive Ballard</name>
<affiliation><inist:fA14 i1="03"><s1>Age Related Diseases, King's College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Brodaty, Henry" sort="Brodaty, Henry" uniqKey="Brodaty H" first="Henry" last="Brodaty">Henry Brodaty</name>
<affiliation><inist:fA14 i1="04"><s1>Primary Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Grossberg, George" sort="Grossberg, George" uniqKey="Grossberg G" first="George" last="Grossberg">George Grossberg</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Neurology and Psychiatry, St Louis University School of Medicine</s1>
<s2>St Louis, Missouri</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Robert, Philippe" sort="Robert, Philippe" uniqKey="Robert P" first="Philippe" last="Robert">Philippe Robert</name>
<affiliation><inist:fA14 i1="06"><s1>Centre Mémoire de Ressources et de Recherche (Memory Centre for Care and Research), CHU de Nice, Hôpital Pasteur</s1>
<s2>Nice</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lyketsos, Constantine" sort="Lyketsos, Constantine" uniqKey="Lyketsos C" first="Constantine" last="Lyketsos">Constantine Lyketsos</name>
<affiliation><inist:fA14 i1="07"><s1>Department of Psychiatry, The Johns Hopkins Bayview Medical Center</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">10-0266370</idno>
<date when="2010">2010</date>
<idno type="stanalyst">FRANCIS 10-0266370 INIST</idno>
<idno type="RBID">Francis:10-0266370</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002A17</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Management of behavioral problems in Alzheimer's disease</title>
<author><name sortKey="Gauthier, Serge" sort="Gauthier, Serge" uniqKey="Gauthier S" first="Serge" last="Gauthier">Serge Gauthier</name>
<affiliation><inist:fA14 i1="01"><s1>Alzheimer's Disease and Related Disorders Unit at the McGill Centerfor Studies in Aging Douglas Mental Health University Institute</s1>
<s2>Montreal</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Cummings, Jeffrey" sort="Cummings, Jeffrey" uniqKey="Cummings J" first="Jeffrey" last="Cummings">Jeffrey Cummings</name>
<affiliation><inist:fA14 i1="02"><s1>Mary S. Easton Center for Alzheimer's Disease Research at UCLA</s1>
<s2>Los Angeles, California</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ballard, Clive" sort="Ballard, Clive" uniqKey="Ballard C" first="Clive" last="Ballard">Clive Ballard</name>
<affiliation><inist:fA14 i1="03"><s1>Age Related Diseases, King's College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Brodaty, Henry" sort="Brodaty, Henry" uniqKey="Brodaty H" first="Henry" last="Brodaty">Henry Brodaty</name>
<affiliation><inist:fA14 i1="04"><s1>Primary Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Grossberg, George" sort="Grossberg, George" uniqKey="Grossberg G" first="George" last="Grossberg">George Grossberg</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Neurology and Psychiatry, St Louis University School of Medicine</s1>
<s2>St Louis, Missouri</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Robert, Philippe" sort="Robert, Philippe" uniqKey="Robert P" first="Philippe" last="Robert">Philippe Robert</name>
<affiliation><inist:fA14 i1="06"><s1>Centre Mémoire de Ressources et de Recherche (Memory Centre for Care and Research), CHU de Nice, Hôpital Pasteur</s1>
<s2>Nice</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lyketsos, Constantine" sort="Lyketsos, Constantine" uniqKey="Lyketsos C" first="Constantine" last="Lyketsos">Constantine Lyketsos</name>
<affiliation><inist:fA14 i1="07"><s1>Department of Psychiatry, The Johns Hopkins Bayview Medical Center</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">International psychogeriatrics</title>
<title level="j" type="abbreviated">Int. psychogeriatr.</title>
<idno type="ISSN">1041-6102</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">International psychogeriatrics</title>
<title level="j" type="abbreviated">Int. psychogeriatr.</title>
<idno type="ISSN">1041-6102</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Alzheimer disease</term>
<term>Behavior</term>
<term>Behavioral disorder</term>
<term>Elderly</term>
<term>Management</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Gestion</term>
<term>Trouble du comportement</term>
<term>Démence d'Alzheimer</term>
<term>Comportement</term>
<term>Traitement</term>
<term>Personne âgée</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Alzheimer's disease (AD) is a complex progressive brain degenerative disorder that has effects on multiple cerebral systems. In addition to cognitive and functional decline, diverse behavioral changes manifest with increasing severity over time, presenting significant management challenges for caregivers and health care professionals. Almost all patients with AD are affected by neuropsychiatric symptoms at some point during their illness; in some cases, symptoms occur prior to diagnosis of the dementia syndrome. Further, behavioral factors have been identified, which may have their origins in particular neurobiological processes, and respond to particular management strategies. Improved clarification of causes, triggers, and presentation of neuropsychiatric symptoms will guide both research and clinical decision-making. Measurement of neuropsychiatric symptoms in AD is most commonly by means of the Neuropsychiatric Inventory; its utility and future development are discussed, as are the limitations and difficulties encountered when quantifying behavioral responses in clinical trials. Evidence from clinical trials of both non-pharmacological and pharmacological treatments, and from neurobiological studies, provides a range of management options that can be tailored to individual needs. We suggest that non-pharmacological interventions (including psychosocial/psychological counseling, interpersonal management and environmental management) should be attempted first, followed by the least harmful medication for the shortest time possible. Pharmacological treatment options, such as antipsychotics, antidepressants, anticonvulsants, cholinesterase inhibitors and memantine, need careful consideration of the benefits and limitations of each drug class.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>1041-6102</s0>
</fA01>
<fA03 i2="1"><s0>Int. psychogeriatr.</s0>
</fA03>
<fA05><s2>22</s2>
</fA05>
<fA06><s2>3</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Management of behavioral problems in Alzheimer's disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>GAUTHIER (Serge)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>CUMMINGS (Jeffrey)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>BALLARD (Clive)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>BRODATY (Henry)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>GROSSBERG (George)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>ROBERT (Philippe)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>LYKETSOS (Constantine)</s1>
</fA11>
<fA14 i1="01"><s1>Alzheimer's Disease and Related Disorders Unit at the McGill Centerfor Studies in Aging Douglas Mental Health University Institute</s1>
<s2>Montreal</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Mary S. Easton Center for Alzheimer's Disease Research at UCLA</s1>
<s2>Los Angeles, California</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Age Related Diseases, King's College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Primary Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Department of Neurology and Psychiatry, St Louis University School of Medicine</s1>
<s2>St Louis, Missouri</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Centre Mémoire de Ressources et de Recherche (Memory Centre for Care and Research), CHU de Nice, Hôpital Pasteur</s1>
<s2>Nice</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Department of Psychiatry, The Johns Hopkins Bayview Medical Center</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA20><s1>346-372</s1>
</fA20>
<fA21><s1>2010</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>26959</s2>
<s5>354000181144060020</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2010 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>7 p.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>10-0266370</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>International psychogeriatrics</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Alzheimer's disease (AD) is a complex progressive brain degenerative disorder that has effects on multiple cerebral systems. In addition to cognitive and functional decline, diverse behavioral changes manifest with increasing severity over time, presenting significant management challenges for caregivers and health care professionals. Almost all patients with AD are affected by neuropsychiatric symptoms at some point during their illness; in some cases, symptoms occur prior to diagnosis of the dementia syndrome. Further, behavioral factors have been identified, which may have their origins in particular neurobiological processes, and respond to particular management strategies. Improved clarification of causes, triggers, and presentation of neuropsychiatric symptoms will guide both research and clinical decision-making. Measurement of neuropsychiatric symptoms in AD is most commonly by means of the Neuropsychiatric Inventory; its utility and future development are discussed, as are the limitations and difficulties encountered when quantifying behavioral responses in clinical trials. Evidence from clinical trials of both non-pharmacological and pharmacological treatments, and from neurobiological studies, provides a range of management options that can be tailored to individual needs. We suggest that non-pharmacological interventions (including psychosocial/psychological counseling, interpersonal management and environmental management) should be attempted first, followed by the least harmful medication for the shortest time possible. Pharmacological treatment options, such as antipsychotics, antidepressants, anticonvulsants, cholinesterase inhibitors and memantine, need careful consideration of the benefits and limitations of each drug class.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>770D05</s0>
<s1>IV</s1>
</fC02>
<fC02 i1="02" i2="X"><s0>770D03M</s0>
<s1>IV</s1>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Gestion</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Management</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Gestión</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Trouble du comportement</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Behavioral disorder</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Trastorno conducta</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Démence d'Alzheimer</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Alzheimer disease</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Demencia Alzheimer</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Comportement</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Behavior</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Conducta</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Traitement</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Treatment</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Personne âgée</s0>
<s5>18</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Elderly</s0>
<s5>18</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Anciano</s0>
<s5>18</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Homme</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Human</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Hombre</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>40</s5>
</fC07>
<fN21><s1>172</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>FRANCIS 10-0266370 INIST</NO>
<ET>Management of behavioral problems in Alzheimer's disease</ET>
<AU>GAUTHIER (Serge); CUMMINGS (Jeffrey); BALLARD (Clive); BRODATY (Henry); GROSSBERG (George); ROBERT (Philippe); LYKETSOS (Constantine)</AU>
<AF>Alzheimer's Disease and Related Disorders Unit at the McGill Centerfor Studies in Aging Douglas Mental Health University Institute/Montreal/Canada (1 aut.); Mary S. Easton Center for Alzheimer's Disease Research at UCLA/Los Angeles, California/Etats-Unis (2 aut.); Age Related Diseases, King's College London/London/Royaume-Uni (3 aut.); Primary Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales/Sydney/Australie (4 aut.); Department of Neurology and Psychiatry, St Louis University School of Medicine/St Louis, Missouri/Etats-Unis (5 aut.); Centre Mémoire de Ressources et de Recherche (Memory Centre for Care and Research), CHU de Nice, Hôpital Pasteur/Nice/France (6 aut.); Department of Psychiatry, The Johns Hopkins Bayview Medical Center/Baltimore, Maryland/Etats-Unis (7 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>International psychogeriatrics; ISSN 1041-6102; Etats-Unis; Da. 2010; Vol. 22; No. 3; Pp. 346-372; Bibl. 7 p.</SO>
<LA>Anglais</LA>
<EA>Alzheimer's disease (AD) is a complex progressive brain degenerative disorder that has effects on multiple cerebral systems. In addition to cognitive and functional decline, diverse behavioral changes manifest with increasing severity over time, presenting significant management challenges for caregivers and health care professionals. Almost all patients with AD are affected by neuropsychiatric symptoms at some point during their illness; in some cases, symptoms occur prior to diagnosis of the dementia syndrome. Further, behavioral factors have been identified, which may have their origins in particular neurobiological processes, and respond to particular management strategies. Improved clarification of causes, triggers, and presentation of neuropsychiatric symptoms will guide both research and clinical decision-making. Measurement of neuropsychiatric symptoms in AD is most commonly by means of the Neuropsychiatric Inventory; its utility and future development are discussed, as are the limitations and difficulties encountered when quantifying behavioral responses in clinical trials. Evidence from clinical trials of both non-pharmacological and pharmacological treatments, and from neurobiological studies, provides a range of management options that can be tailored to individual needs. We suggest that non-pharmacological interventions (including psychosocial/psychological counseling, interpersonal management and environmental management) should be attempted first, followed by the least harmful medication for the shortest time possible. Pharmacological treatment options, such as antipsychotics, antidepressants, anticonvulsants, cholinesterase inhibitors and memantine, need careful consideration of the benefits and limitations of each drug class.</EA>
<CC>770D05; 770D03M</CC>
<FD>Gestion; Trouble du comportement; Démence d'Alzheimer; Comportement; Traitement; Personne âgée</FD>
<FG>Homme; Pathologie de l'encéphale; Maladie dégénérative; Pathologie du   système nerveux central; Pathologie du   système nerveux</FG>
<ED>Management; Behavioral disorder; Alzheimer disease; Behavior; Treatment; Elderly</ED>
<EG>Human; Cerebral disorder; Degenerative disease; Central nervous system disease; Nervous system diseases</EG>
<SD>Gestión; Trastorno conducta; Demencia Alzheimer; Conducta; Tratamiento; Anciano</SD>
<LO>INIST-26959.354000181144060020</LO>
<ID>10-0266370</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002A17 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 002A17 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Francis:10-0266370
   |texte=   Management of behavioral problems in Alzheimer's disease
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Management of behavioral problems in Alzheimer's disease

Management of behavioral problems in Alzheimer's disease

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri